Qualcosa di nuovo nella prevenzione dell'ictus?

Translated title of the contribution: What's new in the prevention of stroke?

Roberto Antonicelli, Giuseppe Germanò

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

More than 186 000 strokes occur every year in Italy, responsible for 10-12% of total mortality. Despite the reduction in mortality and disability, the incidence of stroke is persistently high and mortality within the first month is about 30%; furthermore, the severe residual disability is about 40% in survivors. Large clinical outcome trials have defined the strict correlation between stroke and systolic and diastolic hypertension, and several meta-analyses and intervention studies showed that reduction of blood pressure, independently of the drug used (diuretics, beta-blockers, calcium antagonists, angiotensin-converting enzyme inhibitors), decreases significantly (≥ 30%) stroke mortality and morbidity in hypertensives. Despite numerous and effective antihypertensive drugs, stroke mortality and morbidity in hypertensive subjects remain persistently higher than in normotensive ones. Two recent clinical studies confirmed the great efficacy of angiotensin II antagonists in reducing stroke relative risk in hypertensive patients at elevated cardiovascular risk. The LIFE study demonstrated that an active treatment is superior to another one in reducing the prefixed endpoint. This important result has conferred great expectancy on angiotensin II antagonists and on their possible "class effect". Considering the recent intervention trials and the correct interpretation of the evidence-based medicine, we should not consider all principles as belonging to the same category, equally effective in the prevention of cardiovascular risk. The concept of "class effect" has not a real scientific value and cannot replace the experimental results of clinical studies which represent the only bench test for the efficacy of a drug.

Original languageItalian
Pages (from-to)958-964
Number of pages7
JournalItalian Heart Journal Supplement
Volume4
Issue number12
Publication statusPublished - 2003

Fingerprint

Stroke
Mortality
Angiotensin II
Morbidity
Evidence-Based Medicine
Angiotensin-Converting Enzyme Inhibitors
Diuretics
Pharmaceutical Preparations
Antihypertensive Agents
Italy
Survivors
Meta-Analysis
Clinical Trials
Blood Pressure
Hypertension
Calcium
Incidence
Clinical Studies
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Qualcosa di nuovo nella prevenzione dell'ictus? / Antonicelli, Roberto; Germanò, Giuseppe.

In: Italian Heart Journal Supplement, Vol. 4, No. 12, 2003, p. 958-964.

Research output: Contribution to journalArticle

Antonicelli, Roberto ; Germanò, Giuseppe. / Qualcosa di nuovo nella prevenzione dell'ictus?. In: Italian Heart Journal Supplement. 2003 ; Vol. 4, No. 12. pp. 958-964.
@article{2eadd5316bd44d179ec40c0c863dd560,
title = "Qualcosa di nuovo nella prevenzione dell'ictus?",
abstract = "More than 186 000 strokes occur every year in Italy, responsible for 10-12{\%} of total mortality. Despite the reduction in mortality and disability, the incidence of stroke is persistently high and mortality within the first month is about 30{\%}; furthermore, the severe residual disability is about 40{\%} in survivors. Large clinical outcome trials have defined the strict correlation between stroke and systolic and diastolic hypertension, and several meta-analyses and intervention studies showed that reduction of blood pressure, independently of the drug used (diuretics, beta-blockers, calcium antagonists, angiotensin-converting enzyme inhibitors), decreases significantly (≥ 30{\%}) stroke mortality and morbidity in hypertensives. Despite numerous and effective antihypertensive drugs, stroke mortality and morbidity in hypertensive subjects remain persistently higher than in normotensive ones. Two recent clinical studies confirmed the great efficacy of angiotensin II antagonists in reducing stroke relative risk in hypertensive patients at elevated cardiovascular risk. The LIFE study demonstrated that an active treatment is superior to another one in reducing the prefixed endpoint. This important result has conferred great expectancy on angiotensin II antagonists and on their possible {"}class effect{"}. Considering the recent intervention trials and the correct interpretation of the evidence-based medicine, we should not consider all principles as belonging to the same category, equally effective in the prevention of cardiovascular risk. The concept of {"}class effect{"} has not a real scientific value and cannot replace the experimental results of clinical studies which represent the only bench test for the efficacy of a drug.",
keywords = "ACE-inhibitors, Angiotensin, Hypertension, Stroke",
author = "Roberto Antonicelli and Giuseppe German{\`o}",
year = "2003",
language = "Italian",
volume = "4",
pages = "958--964",
journal = "Italian Heart Journal Supplement",
issn = "1129-4728",
publisher = "Centro Editoriale Pubblicitario Italiano",
number = "12",

}

TY - JOUR

T1 - Qualcosa di nuovo nella prevenzione dell'ictus?

AU - Antonicelli, Roberto

AU - Germanò, Giuseppe

PY - 2003

Y1 - 2003

N2 - More than 186 000 strokes occur every year in Italy, responsible for 10-12% of total mortality. Despite the reduction in mortality and disability, the incidence of stroke is persistently high and mortality within the first month is about 30%; furthermore, the severe residual disability is about 40% in survivors. Large clinical outcome trials have defined the strict correlation between stroke and systolic and diastolic hypertension, and several meta-analyses and intervention studies showed that reduction of blood pressure, independently of the drug used (diuretics, beta-blockers, calcium antagonists, angiotensin-converting enzyme inhibitors), decreases significantly (≥ 30%) stroke mortality and morbidity in hypertensives. Despite numerous and effective antihypertensive drugs, stroke mortality and morbidity in hypertensive subjects remain persistently higher than in normotensive ones. Two recent clinical studies confirmed the great efficacy of angiotensin II antagonists in reducing stroke relative risk in hypertensive patients at elevated cardiovascular risk. The LIFE study demonstrated that an active treatment is superior to another one in reducing the prefixed endpoint. This important result has conferred great expectancy on angiotensin II antagonists and on their possible "class effect". Considering the recent intervention trials and the correct interpretation of the evidence-based medicine, we should not consider all principles as belonging to the same category, equally effective in the prevention of cardiovascular risk. The concept of "class effect" has not a real scientific value and cannot replace the experimental results of clinical studies which represent the only bench test for the efficacy of a drug.

AB - More than 186 000 strokes occur every year in Italy, responsible for 10-12% of total mortality. Despite the reduction in mortality and disability, the incidence of stroke is persistently high and mortality within the first month is about 30%; furthermore, the severe residual disability is about 40% in survivors. Large clinical outcome trials have defined the strict correlation between stroke and systolic and diastolic hypertension, and several meta-analyses and intervention studies showed that reduction of blood pressure, independently of the drug used (diuretics, beta-blockers, calcium antagonists, angiotensin-converting enzyme inhibitors), decreases significantly (≥ 30%) stroke mortality and morbidity in hypertensives. Despite numerous and effective antihypertensive drugs, stroke mortality and morbidity in hypertensive subjects remain persistently higher than in normotensive ones. Two recent clinical studies confirmed the great efficacy of angiotensin II antagonists in reducing stroke relative risk in hypertensive patients at elevated cardiovascular risk. The LIFE study demonstrated that an active treatment is superior to another one in reducing the prefixed endpoint. This important result has conferred great expectancy on angiotensin II antagonists and on their possible "class effect". Considering the recent intervention trials and the correct interpretation of the evidence-based medicine, we should not consider all principles as belonging to the same category, equally effective in the prevention of cardiovascular risk. The concept of "class effect" has not a real scientific value and cannot replace the experimental results of clinical studies which represent the only bench test for the efficacy of a drug.

KW - ACE-inhibitors

KW - Angiotensin

KW - Hypertension

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=6944250149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6944250149&partnerID=8YFLogxK

M3 - Articolo

C2 - 14976861

AN - SCOPUS:6944250149

VL - 4

SP - 958

EP - 964

JO - Italian Heart Journal Supplement

JF - Italian Heart Journal Supplement

SN - 1129-4728

IS - 12

ER -